CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...
Phase 2, Phase 3
Brescia, Italy and 37 other locations
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...
Phase 2, Phase 3
Brescia, Italy and 37 other locations
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick toget ...
Phase 2
Milan, Italy and 37 other locations
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Phase 3
Brescia, Italy and 50 other locations
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...
Phase 2, Phase 3
Milan, Italy and 126 other locations
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease...
Phase 3
Milan, Lombardy, Italy and 111 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...
Phase 3
Monza, Italy and 246 other locations
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (inclu...
Phase 2
Monza, Italy and 96 other locations
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease...
Phase 3
Milan, Lombardy, Italy and 242 other locations
capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 o...
Phase 3
Milano, Lombardia, Italy and 201 other locations
Clinical trials
Research sites
Resources
Legal